Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

Inclusion Criteria:

• Confirmed HCC based on histopathological findings from tumor tissue orradiologically findings

• No prior systemic therapy for HCC

• Barcelona Clinic Liver Cancer (BCLC) stage B (not eligible for locoregional therapy)or stage C

• Child-Pugh Score class A or B

• ECOG performance status (PS) of 0-2 at enrollment (Child-Pugh Score class A and ECOGPS of 0-1 will be enrolled in cohort 1 and Child-Pugh Score class B or ECOG PS of 2will be enrolled in cohort 2)

• At least 1 measurable lesion per RECSIT 1.1 guidelines

Exclusion Criteria:

• Hepatic encephalopathy within past 12 months or requirement for medication toprevent or control encephalopathy

• Clinically meaningful ascites

• Main portal vein tumor thrombosis

• Active or prior documented GI bleeding (eg, esophageal varices or ulcer bleeding)within 6 months

• HBV and HVC co-infection, or HBV and Hep D co-infection